Skip to content

AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac Amyloidosis

AccurKardia, Inc. announced the grant of its US Patent No. 12,620,488 for a machine learning system that detects cardiac amyloidosis using standard 12-lead ECG. Cardiac amyloidosis is a serious heart condition where abnormal proteins accumulate in the heart, leading to complications.

NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company’s proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG. Cardiac amyloidosis is a serious, often fatal heart disease in which abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and even